|
|
Clinical effect of low dose Thalidomide combined with VED chemotherapy in the treatment of elderly patients with newly diagnosed multiple myeloma |
LIN Zhi-juan LUO Yi-ming |
Department of Hematology,the First Affiliated Hospital of Xiamen University,Xiamen 361003,China |
|
|
Abstract ObjectiveTo explore the clinical effect of low dose Thalidomide combined with VED chemotherapy in the treatment of elderly patients with newly diagnosed multiple myeloma.Methods82 elderly patients with newly multiple myeloma in our hospital from July 2011 to June 2016 were selected and randomly divided into the experimental group and the control group,41 cases in each group.The control group was treated with standard VED regimen chemotherapy, the experimental group was treated with low-dose Thalidomide combined with standard dose chemotherapy of VED.The total effective rate,the incidence rate of adverse reaction,Karnofsky score after treatment,hemoglobin index,bone marrow plasma cell count,and serum M protein were compared between the two groups.ResultsThe total effective rate of the experimental group was 85.37%,which was higher than 63.41%of the control group,with significant difference(P<0.05). The number of bone marrow plasma cells and serum M protein after treatment in the experimental group was lower than that in the control group,the Karnofsky score and hemoglobin after treatment in the experimental group was higher than that in the control group,with significant difference (P<0.05).The incidence rate of constipation and mild sleepiness in the experimental group was higher than that in the control group,with significant difference (P<0.05).There was no significant difference in the incidence rate of the rest adverse reactions between the two groups(P>0.05).After treatment, the patient′s symptoms of mild sleepiness and constipation were significantly alleviated,which did not affect the treatment.ConclusionFor elderly patients with newly diagnosed multiple myeloma,the application of low dose Thalidomide combined with chemotherapy is safe and effective,were well tolerated,with good clinical feasibility,it is worthy of further promotion and application.
|
|
|
|
|
[1] |
中国多发性骨髓瘤诊治指南(2015年修订)[J]中华内科杂志,2015,54(12):1066-1070.
|
[2] |
周志刚,陈亚峰,张云平,等.低剂量沙利度胺联合化疗治疗老年多发性骨髓瘤的疗效观察[J].中华肿瘤防治杂志,2015,22(11):197-198.
|
[3] |
刘宇,武操,史克倩.四种治疗多发性骨髓瘤方案的疗效评价[J].中国新药与临床杂志,2014,33(10):756-759.
|
[4] |
王贵锋.沙利度胺联合MP及VAD方案治疗多发性骨髓瘤42例[J].中国医药导报,2010,7(28):59-60.
|
[5] |
周章军,陈建才,王新珠,等.沙利度胺联合化疗治疗多发性骨髓瘤疗效观察[J].中国医师进修杂志,2007,30(19):54-55.
|
[6] |
赵伟鹏,于泳,张翼鷟.多发性骨髓瘤化疗后维持治疗药物的应用进展[J].山东医药,2015,55(7):90-92.
|
[7] |
王洪真.沙利度胺联合VAD化疗方案对多发性骨髓瘤临床疗效的系统评价[J].中国医药导报,2012,9(30):41-44.
|
[8] |
吴燕明,丁刚,丁厚明.沙利度胺联合化疗治疗多发性骨髓瘤的临床观察[J].蚌埠医学院学报,2006,31(5):497-498.
|
[9] |
丛琳,肖静,张文娟,等.沙利度胺、帕米膦酸二钠联合化疗治疗多发性骨髓瘤的疗效观察[J].世界临床药物,2009,30(9):542-545.
|
[10] |
何群,陈曙平,祝焱,等.沙利度胺联合化疗治疗难治性多发性骨髓瘤16例[J].实用医学杂志,2007,23(8):1234-1235.
|
[11] |
翟欣辉,王一,连小贇,等.小剂量沙利度胺治疗多发性骨髓瘤临床观察及对VEGF及MVD的影响[J].陕西医学杂志,2012,41(2):216-218.
|
[12] |
丁晓庆,赵鹏,孙海燕,等.中药、化疗配合沙利度胺治疗多发性骨髓瘤回顾性疗效分析[J].国际中医中药杂志,2011,33(4):297-300.
|
[13] |
刘俊茹,李娟,赵莹,等.含沙利度胺的联合化疗方案与沙利度胺单药对复发难治多发性骨髓瘤的疗效比较[J].中国实用内科杂志,2009,29(12):1115-1117.
|
[14] |
陈莉莉,王友群,江文华,等.沙利度胺联合化疗治疗多发性骨髓瘤的临床观察[J].中国医院药学杂志,2005,25 (8):755-756.
|
[15] |
刘传才,陈文习.沙利度胺联合化疗治疗多发性骨髓瘤的临床观察[J].医学综述,2014,20(17):3226-3227.
|
|
|
|